Cost Effectiveness of Tofacitinib for the Treatment of Moderate to Severe Active Ulcerative Colitis in Colombia

OBJECTIVE: The aim of this study was to evaluate the cost effectiveness of tofacitinib versus other treatment options currently available in Colombia in naïve to biologics (first-line) and exposed to biologics (second-line) patients with moderate to severe active ulcerative colitis (UC). METHODS: A...

Descripción completa

Detalles Bibliográficos
Autores principales: Gil, Fabio, Juliao-Baños, Fabian, Amador, Luisa, Castano, Natalia, Reyes, Juan Manuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9596638/
https://www.ncbi.nlm.nih.gov/pubmed/35943702
http://dx.doi.org/10.1007/s41669-022-00360-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9596638/
https://www.ncbi.nlm.nih.gov/pubmed/35943702
http://dx.doi.org/10.1007/s41669-022-00360-4

Ejemplares similares